Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| GMP-L12H23 | Human | GMP Human IL-12 Protein |
|
||
| IL2-H5210 | Human | Human IL-12 Protein, premium grade |
|
|
|
| IL2-H8210 | Human | Biotinylated Human IL-12B&IL-12A Heterodimer Protein, His,Avitag™&Flag Tag |  |
|
|
| IL2-H4210 | Human | Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (MALS verified) |  |
|
|
GMP Human IL-12 Protein (Cat. No. GMP-L12H23) stimulates secretion of IFN-γ by NK-92. The specific activity of GMP Human IL-12 Protein is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-12 WHO International Standard (NIBSC code: 95/544) (QC tested).
Human IL-12 Protein, premium grade (Cat. No. IL2-H5210) stimulates secretion of IFN-γ by NK-92 human natural killer lymphoma cells. The specific activity of Human IL-12 Protein, premium grade is > 1.00ⅹ10^7 IU/mg, which is calibrated against human IL-12 WHO International Standard (NIBSC code: 95/544) (QC tested).
Human IL-12 R beta 1, Fc Tag (Cat. No. ILB-H5255) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human IL-12B&IL-12A Heterodimer Protein, His Tag&Flag Tag (Cat. No. IL2-H4210) with an affinity constant of 2.06 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab | C-340; CNTO-1275 | Approved | Johnson & Johnson Innovative Medicine | Stelara, 喜达诺 | United States | Plaque psoriasis | Janssen Biotech Inc | 2009-09-25 | Multiple Sclerosis; Plaque psoriasis; Dermatitis, Atopic; Crohn Disease; Hidradenitis Suppurativa; Common Variable Immunodeficiency; Uveitis; Colitis, Ulcerative; Arthritis, Psoriatic; Takayasu Arteritis; Lupus Erythematosus, Systemic; Psoriasis; Diabetes Mellitus, Type 1; Arthritis, Juvenile; Sjogren's Syndrome; Spondylitis, Ankylosing; Pouchitis; Ichthyosis; Dermatomyositis; Inflammatory Bowel Diseases; Type I Leukocyte Adhesion Defect; Polymyositis; Liver Cirrhosis, Biliary | Details |
| Ustekinumab biosimilar(Formycon) | FYB-202 | Approved | Formycon AG | OTULFI | EU | Crohn Disease; Colitis, Ulcerative | Fresenius Kabi Deutschland Gmbh, Formycon AG | 2024-09-25 | Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab Biosimilar (qyuns) | QX-001S; QX-001-S; HDM-3001 | Approved | Qyuns Therapeutics Co Ltd | Mainland China | Plaque psoriasis | Qyuns Therapeutics Co Ltd | 2024-10-29 | Psoriasis; Plaque psoriasis | Details | |
| Ustekinumab Biosimilar(Celltrion) | CT-P43 | Approved | Celltrion Inc | Steqeyma, Steqeyma IV | Canada | Plaque psoriasis; Arthritis, Psoriatic; Crohn Disease | Celltrion Inc | 2024-08-01 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab biosimilar (Biocon) | Approved | Biocon Biologics Ltd | Bmab 1200, Yesintek | United States | Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease | Biocon Biologics Inc | 2024-11-29 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details | |
| Ustekinumab biosimilar (Alvotech) | AVT04; AVT-04 | Approved | Alvotech hf | Jamteki, Uzpruvo, SELARSDI™, JamtekiTM, Ustekinumab BS (F) | Japan | Arthritis, Psoriatic; Psoriasis | Fuji Pharma Co Ltd | 2023-09-25 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Plaque psoriasis; Crohn Disease | Details |
| Ustekinumab biosimilar(Amgen) | ABP-654 | Approved | Amgen Inc | Wezlana, WEZLANA, wezenla | United States | Crohn Disease; Colitis, Ulcerative; Arthritis, Psoriatic; Plaque psoriasis | Amgen Inc | 2023-10-31 | Psoriasis; Arthritis, Psoriatic; Colitis, Ulcerative; Crohn Disease; Plaque psoriasis | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Xerostomia; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Osteosarcoma; Cholangitis, Sclerosing; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Epilepsy; Erythema Nodosum; Sarcoma; HIV Wasting Syndrome; Pancreatitis, Chronic; Sarcoma, Ewing; Arachnoiditis; Gastrointestinal Hemorrhage; Retinoblastoma; Prostatic Neoplasms; Endometriosis; Lung Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Carcinoma, Hepatocellular; Burning Mouth Syndrome; Stomatitis; Neoplasm Metastasis; Appendiceal Neoplasms; Tuberculosis; Lymphoma, Non-Hodgkin; Angiodysplasia; Pelvic Pain; Glioma; Waldenstrom Macroglobulinemia; Leprosy, Lepromatous; Endometrial Neoplasms; Uterine Neoplasms; Anemia, Sideroblastic; Ovarian Neoplasms; Gastric Antral Vascular Ectasia; Lupus Erythematosus, Discoid; Carc | Details |
| Ustekinumab biosimilar(DM Bio) | DA-3115; DMB-3115 | Approved | Dong-A Pharmaceutical Co Ltd, Meiji Seika Pharma Co Ltd | IMULDOSA, Absimky | United States | Psoriasis | Dong-A ST Co Ltd, Meiji Seika Kaisha Ltd | 2024-10-11 | Psoriasis; Colitis, Ulcerative; Crohn Disease | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Lisofylline | BL-194; CT-1501R; A-802710 | Phase 3 Clinical | Cti Biopharma Corp | Diabetes Mellitus, Type 1; Rejection of organ transplantation | Details |
| Apilimod mesilate | AIT-101; STA-5326-mesylate; LAM-002; STA-5326; LAM-002A | Phase 2 Clinical | Madrigal Pharmaceuticals Inc, Lam | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Common Variable Immunodeficiency; Crohn Disease; Amyotrophic Lateral Sclerosis | Details |
| NSC-733972 | M-032; M032-H SV-1; NSC-733972 | Phase 2 Clinical | University Of Alabama At Birmingham | Glioblastoma; Gliosarcoma; Astrocytoma | Details |
| Tavokinogene telseplasmid | DNA IL-12; pIL-12 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | HIV Infections; Hemorrhagic Fever, Ebola; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Prostatic Neoplasms; Hepatitis B; Lymphoma, T-Cell, Cutaneous; Melanoma; Mycosis Fungoides | Details |
| T-3011 | T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 | Phase 2 Clinical | Immvira Co Ltd | Sarcoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Colorectal Neoplasms; Breast Neoplasms; Solid tumours; Urinary Bladder Neoplasms; Mesothelioma; Ascites; Skin Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms | Details |
| PDS-0301 | M-9241; MSB-0010360; MSB0010360; PDS-0301 | Phase 2 Clinical | Emd Serono Inc, Merck Serono, National Cancer Institute | Prostatic Neoplasms; Sarcoma, Kaposi; Uterine Cervical Neoplasms; Urogenital Neoplasms; Metastatic breast cancer; Penile Neoplasms; Bile Duct Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Cholangiocarcinoma; Vulvar Neoplasms; Breast Neoplasms; Head and Neck Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Colonic Neoplasms; Papillomavirus Infections; Rectal Neoplasms; Carcinoma; Vaginal Neoplasms; Anus Neoplasms; Intestinal Neoplasms | Details |
| XTX-301 | XTX-301 | Phase 2 Clinical | Solid tumours; Neoplasms | Details | |
| STX-001 | STX-001 | Phase 2 Clinical | Massachusetts Institute Of Technology | Solid tumours; Triple Negative Breast Neoplasms; Melanoma | Details |
| JCXH-211 | JCXH-211 | Phase 2 Clinical | Immorna (Hangzhou) Biotechnology Co., Ltd | Solid tumours; Neoplasms; Skin Neoplasms; Glioma | Details |
| Recombinant Human nsIL12 Oncolytic Adenovirus (Beijing Haute Biotechnology) | BioTTT-001; BioTTT001 | Phase 2 Clinical | Beijing Bio-Targeting Therapeutics Technology Co Ltd | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Glioma | Details |
| Recombinant Human IL12/15-PDL1B Herpes Simplex Type I Oncolytic Virus (Cnbg-Virogin Biotech (Shanghai) Ltd) | VG-161 | Phase 2 Clinical | Cnbg-Virogin Biotech (Shanghai) Ltd | Solid tumours; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Pancreatic Neoplasms; Cholangiocarcinoma; Sarcoma; Carcinoma, Hepatocellular | Details |
| Rocakinogene sifuplasmid | INO-9012 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Glioblastoma; Precancerous Conditions; Carcinoma, Hepatocellular; Vulvar Diseases; Lung Neoplasms; Hepatitis C; Squamous Intraepithelial Lesions of the Cervix; Colorectal Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Hemorrhagic Fever, Ebola; Urogenital Abnormalities; Papillomavirus Infections; Neoplasms, Glandular and Epithelial; Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms; Hepatitis, Chronic; HIV Infections | Details |
| SFA-002 | SFA-002; SFA002 | Phase 1 Clinical | Arthritis, Rheumatoid; Plaque psoriasis | Details | |
| VG-201 | VG-201 | Phase 1 Clinical | ViroGin Biotech Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| VG-203 | VG-203; VG2062; VG-2062 | Phase 1 Clinical | ViroGin Biotech Ltd, Shanghai Funuojian Biotechnology Co Ltd, Virogin Biotech (Shenzhen) Ltd, Fenojian Biotechnology (Nantong) Co Ltd | Solid tumours; Ovarian Neoplasms; Carcinoma, Renal Cell; Breast Neoplasms | Details |
| MVR-C5252 | C-5252; MVR-C5252; T-5 | Phase 1 Clinical | Immvira Co Ltd | Solid tumours; Ganglioglioma; Glioblastoma; Brain Neoplasms; Glioma | Details |
| WTX-330 | WTX-330 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours; Neoplasms; Lymphoma, Non-Hodgkin | Details |
| WTX-124 | WTX-124 | Phase 1 Clinical | Werewolf Therapeutics Inc | Solid tumours | Details |
| Ustekinumab biosimilar (Curateq Biologics) | BP38; BP-38 | Phase 1 Clinical | CuraTeQ Biologics Pvt Ltd | Psoriasis | Details |
| IL-12 DNA(NIAID) | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | HIV Infections | Details | |
| SW-0715 | SW-0715 | Phase 1 Clinical | Stemirna Therapeutics | Solid tumours | Details |
| KGX-101 | KGX101; KGX-101(IL-12-Fc融合蛋白); KGX-101(改造优化的细胞因子IL12前药分子); KGX-101 | Phase 1 Clinical | Shanghai KangaBio Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| Ustekinumab Biosimilar (NeuClone/Serum Institute of India) | Phase 1 Clinical | Neuclone, Serum Institute Of India Ltd | Autoimmune Diseases | Details | |
| TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
| Ustekinumab biosimilar(Rani Therapeutics) | RT-111 | Phase 1 Clinical | Rani Therapeutics Llc | Psoriasis | Details |
| ABOD-2011 | ABOD-2011 | Phase 1 Clinical | Cancer Hospital Of Chinese Academy Of Medical Sciences | Solid tumours | Details |
| DF-6002 | DF-6002 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| EGFR IL12 CART | Phase 1 Clinical | Colorectal Neoplasms | Details | ||
| MEDI-1191 | MEDI-1191; MEDI1191 | Phase 1 Clinical | Moderna Inc | Solid tumours; Neoplasms | Details |
| MEDI-9253 | Phase 1 Clinical | Astrazeneca Plc | Solid tumours | Details | |
| Veledimex | INXN-1001; AD-1001 | Ziopharm Oncology Inc | Details | ||
| bacTRL-IL-12 | IQVIA RDS Pty Ltd | Details | |||
| Ustekinumab biosimilar (BioFactura) | BFI-751 | BioFactura Australia Pty Ltd | Details | ||
| INXN-2001 | Ad-IL-12; ZIN-ATI-001; Ad-RTS-hIL-12; Ad-RTS-mIL-12; INXN-2001; Ad-RTS-IL-12; INXN-2001 (Ad-RTS-IL-12) | Ziopharm Oncology Inc | Details |
This web search service is supported by Google Inc.
A-Z
